Literature DB >> 12899526

Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer.

Michael Friedrich1, Leyla Rafi, Tanja Mitschele, Wolfgang Tilgen, Werner Schmidt, Jörg Reichrath.   

Abstract

1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is the biologically active metabolite of vitamin D and has been shown to regulate the growth of various cell types. There are two principal enzymes involved in the formation of circulating 1,25(OH)2D3 from vitamin D, the vitamin D 25-hydroxylase (25-OHase) and the 1alpha-hydroxylase (1alpha-OHase). Recently, extrarenal activity of 1alpha-OHase has been reported in various cell types. The aim of this study was to analyze expression of VDR and the main enzymes involved in the synthesis and metabolism of calcitriol in gynecological malignancies and corresponding normal tissue. Expression of VDR, 25-OHase, 1alpha-OHase, and 24-OHase was analyzed in breast carcinomas (BC), ovarian cancer (OC), cervix carcinomas (CC) and normal corresponding tissues using real-time PCR and specific hybridization probes as well as using immunohistochemistry. RNA for VDR, 1alpha-OHase, 24-OHase and 25-OHase was up-regulated in breast cervical and ovarian carcinomas as compared to normal tissue. VDR immunoreactivity was increased in breast and ovarian cancer and in cervix carcinomas as compared to normal corresponding tissue. Our findings indicate that cervical carcinomas, breast cancer and ovarian cancer may be considered as potential targets for prevention or therapy with new vitamin D analogs that exert little or no calcemic side effects or by pharmacological modulation of 1,25(OH)2D3 synthesis and metabolism in these tumor cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12899526     DOI: 10.1007/978-3-642-55580-0_17

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  49 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.

Authors:  Wei Luo; Adam R Karpf; Kristin K Deeb; Josephia R Muindi; Carl D Morrison; Candace S Johnson; Donald L Trump
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

3.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

4.  The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis.

Authors:  Henrik C Horváth; Péter Lakatos; János P Kósa; Krisztián Bácsi; Katalin Borka; Giovanna Bises; Thomas Nittke; Pamela A Hershberger; Gábor Speer; Enikö Kállay
Journal:  J Histochem Cytochem       Date:  2009-11-09       Impact factor: 2.479

5.  Vitamin d and the risk of uterine fibroids.

Authors:  Donna Day Baird; Michael C Hill; Joel M Schectman; Bruce W Hollis
Journal:  Epidemiology       Date:  2013-05       Impact factor: 4.822

6.  Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  D Michal Freedman; Shih-Chen Chang; Roni T Falk; Mark P Purdue; Wen-Yi Huang; Catherine A McCarty; Bruce W Hollis; Barry I Graubard; Christine D Berg; Regina G Ziegler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

7.  25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture.

Authors:  Xinjian Peng; Michael Hawthorne; Avani Vaishnav; René St-Arnaud; Rajendra G Mehta
Journal:  Breast Cancer Res Treat       Date:  2008-01-20       Impact factor: 4.872

8.  Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Authors:  Shoko Kure; Katsuhiko Nosho; Yoshifumi Baba; Natsumi Irahara; Kaori Shima; Kimmie Ng; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-29       Impact factor: 4.254

9.  Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.

Authors:  Wei Zheng; Kim N Danforth; Shelley S Tworoger; Marc T Goodman; Alan A Arslan; Alpa V Patel; Marjorie L McCullough; Stephanie J Weinstein; Laurence N Kolonel; Mark P Purdue; Xiao-Ou Shu; Kirk Snyder; Emily Steplowski; Kala Visvanathan; Kai Yu; Anne Zeleniuch-Jacquotte; Yu-Tang Gao; Susan E Hankinson; Chinonye Harvey; Richard B Hayes; Brian E Henderson; Ronald L Horst; Kathy J Helzlsouer
Journal:  Am J Epidemiol       Date:  2010-06-18       Impact factor: 4.897

Review 10.  Vitamin D and calcium insufficiency-related chronic diseases: an emerging world-wide public health problem.

Authors:  Meinrad Peterlik; Steven Boonen; Heide S Cross; Christel Lamberg-Allardt
Journal:  Int J Environ Res Public Health       Date:  2009-10-02       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.